All existing shareholders contributed to the Marine Biological Laboratory spinout’s series B round, following a $91.5m series A in mid-2020.
Korro Bio, a US-based RNA editing technology developer based on research at University of Chicago-affiliated Marine Biological Laboratory, secured $116m in series B financing led by Eventide Asset Management last week.
Fidelity Management & Research, Invus, Point72, Verition Fund Management, Monashee Investment Management, Sixty Degree Capital and an unnamed healthcare specialist fund invested in the company alongside all existing backers.
Existing shareholders include Atlas Venture, New Enterprise Associates (NEA), Wu Capital, Qiming Venture Partners USA, Surveyor Capital, Cormorant Asset Management,…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
